EUVIMEDObjevte EUVIMED
BeobachtungsstudieOpen access · CC BY-NC-ND 4.0

A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis

Amelework Wodajo iD, Ravi Sarode, Shiney Valiyaparambil, Christopher Webb iD, Nicole De Simone, Dill Rebecca, Amena Usmani iD

Transfusion · 2024

DOI: 10.1111/trf.17865 ↗

At a glance

Beobachtungsstudie in Transfusion, 2024. Written by Amelework Wodajo and 6 co-authors. Institution: Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Plasma Exchange, Fibrinogen, Hemorrhage. Cited 14 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Plasma exchange (PLEX) therapy is indicated for several disorders. The 5% albumin is often used as a sole replacement fluid during most PLEX. However, each 1.0 plasma volume exchange depletes coagulation factors by ~65%. Although most coagulation factors recover to hemostatic levels within 24 h post‐PLEX, fibrinogen requires 48–72 h to recover. Fibrinogen is the key coagulation protein for hemostasis. Therefore, fibrinogen is often monitored during the acute course of PLEX, and plasma is supplemented to prevent bleeding if fibrinogen is 100 mg/dL.

Results

Among the 275 patients who received 1406 PLEXes, 62 patients (23%) who underwent 323 PLEXes met the inclusion criteria, and only 2 (3%) patients had bleeding while on oral anticoagulants. In contrast, out of 275 patients, 143 (52%) with fibrinogen levels >100 mg/dL received 751 PLEX treatments, and bleeding occurred in 2 (1%) while on low‐molecular‐weight heparin.

Conclusions

Our findings suggest that a pre‐procedure fibrinogen threshold of 80–100 mg/dL without plasma supplementation does not increase bleeding risk unless patients were on anticoagulation.

Subjects

MeSH terms (MEDLINE)

Plasma ExchangeFibrinogenHemorrhageHumansProspective StudiesMaleFemaleMiddle AgedAgedAdultRisk Factors

Author keywords

anticoagulationbleedingfibrinogenplasma exchangeplasma exchange‐induced coagulopathy

Substances

Fibrinogen

Authors and institutions

  • Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Internal Medicine (Hematology/Oncology), Dallas, Texas, USA.
  • Carter BloodCare, Bedford, Texas, USA.
  • Department of Pathology, University of California San Diego, San Diego, California, USA.

ORCID profiles: Amelework Wodajo, Christopher Webb, Amena Usmani

Cite

APA

Wodajo, A., Sarode, R., Valiyaparambil, S., Webb, C., De Simone, N., Rebecca, D., & Usmani, A. (2024). A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis. Transfusion. https://doi.org/10.1111/trf.17865

Vancouver

Wodajo A, Sarode R, Valiyaparambil S, Webb C, De Simone N, Rebecca D, et al. A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis. Transfusion. 2024. doi:10.1111/trf.17865

BibTeX
@article{Wodajo2024,
  author = {Wodajo, Amelework and Sarode, Ravi and Valiyaparambil, Shiney and Webb, Christopher and De Simone, Nicole and Rebecca, Dill and Usmani, Amena},
  title = {A lower fibrinogen threshold does not lead to increased bleeding risk in patients receiving therapeutic plasma exchange: A prospective single‐center analysis},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17865}
}
Start for free →